Knoll Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Knoll Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.25M	Hold	5,475,516	–	–	5.14%	7
2025 Q4	$28.4M	Hold	5,475,516	–	–	13.01%	1
2025 Q3	$28.6M	Hold	5,475,516	–	–	15.32%	1
2025 Q2	$21M	Hold	5,475,516	–	–	14.91%	1
2025 Q1	$31.5M	Hold	5,475,516	–	–	20.48%	1
2024 Q4	$27.3M	Hold	5,475,516	–	–	17.59%	2
2024 Q3	$29.5M	Hold	5,475,516	–	–	13.68%	3
2024 Q2	$18.1M	Hold	5,475,516	–	–	12.21%	3
2024 Q1	$17.9M	Hold	5,475,516	–	–	11.14%	3
2023 Q4	$19.2M	Buy	5,475,516 +2,443,601	+81%	+$7.54M	15.92%	2
2023 Q3	$20.3M	Buy	3,031,915 +16,247	+0.5%	+$121K	21.02%	1
2023 Q2	$25.3M	Buy	3,015,668 +948,508	+46%	+$9.35M	30.67%	1
2023 Q1	$20.5M	Buy	2,067,160 +119,070	+6%	+$842K	31.63%	1
2022 Q4	$13.6M	Buy	1,948,090 +70,785	+4%	+$405K	30.6%	1
2022 Q3	$10M	Buy	1,877,305 +374,845	+25%	+$2.25M	5.86%	2
2022 Q2	$6M	Buy	1,502,460 +743,055	+98%	+$2.56M	3.42%	2
2022 Q1	$3.38M	Hold	759,405	–	–	2.12%	5
2021 Q4	$3.04M	Buy	759,405 +190,000	+33%	+$1.45M	1.67%	9
2021 Q3	$5M	Hold	569,405	–	–	2.49%	6
2021 Q2	$6.45M	Hold	569,405	–	–	3.37%	6
2021 Q1	$6.76M	Hold	569,405	–	–	4.41%	6
2020 Q4	$3.91M	Hold	569,405	–	–	2.66%	7
2020 Q3	$4.22M	Hold	569,405	–	–	3.46%	6
2020 Q2	$2.37M	Hold	569,405	–	–	1.37%	10
2020 Q1	$1.41M	Hold	569,405	–	–	1.32%	12
2019 Q4	$3.31M	Buy	569,405 +37,837	+7%	+$219K	2.44%	9
2019 Q3	$2.8M	Buy	531,568 +2,178	+0.4%	+$11.7K	2.56%	10
2019 Q2	$3.18M	Buy	529,390 +45,294	+9%	+$341K	2.6%	9
2019 Q1	$4.37M	Hold	484,096	–	–	3.32%	8
2018 Q4	$4.02M	Hold	484,096	–	–	4.57%	5
2018 Q3	$6.32M	Buy	484,096 +360,000	+290%	+$2.92M	5.34%	4
2018 Q2	$987K	Hold	124,096	–	–	0.84%	11
2018 Q1	$931K	Hold	124,096	–	–	0.96%	9
2017 Q4	$844K	Hold	124,096	–	–	0.74%	10
2017 Q3	$893K	Hold	124,096	–	–	0.76%	11
2017 Q2	$583K	Hold	124,096	–	–	0.77%	11
2017 Q1	$620K	Sell	124,096 -11,704	-9%	-$60.3K	0.93%	13
2016 Q4	$727K	Hold	135,800	–	–	1.28%	13
2016 Q3	$1.04M	Hold	135,800	–	–	1.82%	11
2016 Q2	$773K	Hold	135,800	–	–	0.25%	13
2016 Q1	$569K	Hold	135,800	–	–	0.23%	16
2015 Q4	$921K	Hold	135,800	–	–	0.34%	14
2015 Q3	$792K	Hold	135,800	–	–	0.34%	11
2015 Q2	$1.05M	Hold	135,800	–	–	0.34%	13
2015 Q1	$1.38M	Buy	+135,800	New	+$1.39M	0.4%	9

Other funds holding ALDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Knoll Capital Management's ALDX Position: Q1 2026 in Review

Knoll Capital Management held its Aldeyra Therapeutics (ALDX) position steady in Q1 2026 at 5,475,516 shares worth $9.25M. The position accounts for 5.14% of the portfolio, ranked #7.

Knoll Capital Management first reported a position in ALDX in Q1 2015 and has held it in 45 quarters since. The position peaked at $31.5M in Q1 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Knoll Capital Management held 5,475,516 shares of Aldeyra Therapeutics worth $9.25M as of Q1 2026.
Knoll Capital Management left its Aldeyra Therapeutics share count unchanged in Q1 2026.
Aldeyra Therapeutics made up 5.14% of Knoll Capital Management's portfolio in Q1 2026, its #7 holding.
Knoll Capital Management first reported a position in Aldeyra Therapeutics in Q1 2015 and has held it in 45 quarters since.
Knoll Capital Management's Aldeyra Therapeutics position peaked at $31.5M in Q1 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.